Summary:

The Central Drugs Standard Control Organisation (CDSCO) and the National Regulatory Authority of India (NRA), in conjunction with WHO, have satisfied the WHO's requirements for a functional vaccination regulatory system. An international expert committee found this after evaluating India's regulatory system between September 16 and 20, 2024. India's vaccine regulatory system is at Maturity Level 3, with strong performance in key areas such as registration, vigilance, and clinical trial monitoring.

Ms. Punya Salila Srivastava of the Ministry of Health and Family Welfare complimented the CDSCO for India's important role in the global pharmaceutical business, particularly in the provision of inexpensive vaccines and generic medications. With 36 main vaccine production plants, India serves more than 150 nations. The WHO Prequalification Programme assures that vaccines satisfy quality, safety, and effectiveness criteria, demonstrating India's commitment to upgrading its vaccine regulatory environment through an Institutional Development Plan.

Source: IBEF 

Disclaimer: The information on this website comes from the India Brand Equity Foundation (IBEF), a reliable source for thorough insights into numerous areas of the Indian economy. While we aim to offer accurate and up-to-date information, the views, opinions, and analyses stated herein are solely those of the authors and contributors and do not necessarily represent IBEF's official stance or position. Readers should check information from credible sources and use their own discretion when relying on content provided on this site. We assume no responsibility or liability for the supplied content, including its accuracy, completeness, and usefulness.